GPCR News 

Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR

Targeting the M1 muscarinic receptor in neurodegenerative disease

Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer

AcroScreen co-founder Margaux Duchamp has been selected as a 30 under 30 Europe Forbes ranking 2022

GPCR Therapeutics Expands Scientific Advisory Board

Domain Therapeutics Raises $42m Series A Financing

John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...

Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...

Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist

Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...

Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering

Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...

Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...

Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...

ShouTi Pharma CEO Dr. Raymond Stevens was interviewed by Moira Gunn of the NPR TechNation podcast

Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...

Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...

Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10

Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...

Exscientia welcomes Richard J. Law, as their new Chief Business Officer

Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology